Stock OVID OVID THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ovid Therapeutics Inc.

Equities

OVID

US6904691010

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-21 EDT 		5-day change 1st Jan Change
0.78 USD +11.27% Intraday chart for Ovid Therapeutics Inc. -76.29% -75.78%
06-18 Oppenheimer Downgrades Ovid Therapeutics to Market Perform MT
06-18 B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat
AQ
Oppenheimer Downgrades Ovid Therapeutics to Market Perform
MT
B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating
MT
BTIG Adjusts Price Target on Ovid Therapeutics to $5 From $11, Maintains Buy Rating
MT
HC Wainwright Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating
MT
Citigroup Adjusts Price Target on Ovid Therapeutics to $1.20 From $3.50, Maintains Neutral Rating
MT
Top Midday Decliners
MT
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback
DJ
Sector Update: Health Care Stocks Decline Premarket Monday
MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell
MT
Wedbush Lowers PT on Ovid Therapeutics to $4 From $8 After Soticlestat Missed Endpoints in Phase 3 Studies; Maintains Outperform Rating
MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall
MT
Top Premarket Decliners
MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies
DJ
Ovid Therapeutics : Corporate Presentation
PU
Takeda's seizure drug fails to meet main goal in late-stage studies
RE
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
GL
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome
CI
Earnings Flash (OVID) OVID THERAPEUTICS Posts Q1 Revenue $148,000
MT
Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OVID Stock
  4. News Ovid Therapeutics Inc.